ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Royalty Pharma PLC

Royalty Pharma PLC (RPRX)

26.465
0.245
( 0.93% )
更新日時: 04:42:42

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

通貨
26.465
買値
26.46
売値
26.47
出来高
1,875,264
26.23 日の範囲 26.665
25.1001 52 週間の範囲 31.655
時価総額
前日終値
26.22
始値
26.26
最終取引時間
04:42:42
財務取引量
US$ 49,804,381
VWAP
26.5586
平均取引量 (3 か月)
2,311,686
発行済株式数
589,182,783
配当利回り
3.17%
PER
13.82
1 株当たり利益 (EPS)
1.93
歳入
2.35B
純利益
1.13B

Royalty Pharma PLC について

Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalti... Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Bristol, Gbr
設立
-
Royalty Pharma PLC is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker RPRX. The last closing price for Royalty Pharma was US$26.22. Over the last year, Royalty Pharma shares have traded in a share price range of US$ 25.1001 to US$ 31.655.

Royalty Pharma currently has 589,182,783 shares in issue. The market capitalisation of Royalty Pharma is US$15.45 billion. Royalty Pharma has a price to earnings ratio (PE ratio) of 13.82.

RPRX 最新ニュース

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare

Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer FoundationThe Prize includes a...

Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million

RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemiaTransaction increases Royalty Pharma’s synthetic...

Royalty Pharma Reports Third Quarter 2024 Results

Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital Deployment of approximately $1.2 billion Raising...

Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800...

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ PR Newswire WALTHAM, Mass. and NEW YORK, Nov. 4, 2024 Proceeds expected to support the...

Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before...

Royalty Pharma Declares Fourth Quarter 2024 Dividend

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
10.5752.2209347238325.8926.66525.1001414486625.86402178CS
4-0.775-2.8450807635827.2428.3625.1001293134926.38961386CS
12-2.385-8.2668977469728.8529.3725.1001231168627.32544721CS
26-0.865-3.1650201244127.3329.3725.1001254836627.22028043CS
52-0.445-1.6536603493126.9131.65525.1001262267728.03845676CS
156-15.775-37.346117424242.2444.7525.1001218604333.33979066CS
26025.79538500.6757.50.67219092836.61548909CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
CRNCCerence Inc
US$ 6.225
(120.74%)
65.83M
WORXSCWorx Corporation
US$ 2.04
(108.16%)
130.1M
SPAISafe Pro Group Inc
US$ 4.604
(43.88%)
39.5M
ARQQArqit Quantum Inc
US$ 10.12
(37.87%)
636.56k
INVZWInnoviz Technologies Ltd
US$ 0.07
(37.86%)
6.41k
SKKSKK Holdings Limited
US$ 0.8194
(-82.03%)
24.88M
WCTWellchange Holdings Company Limited
US$ 1.0302
(-68.97%)
1.84M
TMTCTMT Acquisition Corporation
US$ 2.51
(-61.02%)
338.38k
GLXGGalaxy Payroll Group Ltd
US$ 1.81
(-53.71%)
2.19M
TMTCUTMT Acquisition Corporation
US$ 3.20
(-52.10%)
11.54k
CDTConduit Pharmaceuticals Inc
US$ 0.1099
(19.07%)
555.45M
NVDANVIDIA Corporation
US$ 147.5001
(1.10%)
320.47M
ELABElevai Labs Inc
US$ 0.0203
(-5.14%)
210.24M
AKTSAkoustis Technologies Inc
US$ 0.1003
(15.15%)
199.48M
MARAMARA Holdings Inc
US$ 25.4355
(12.40%)
132.43M

RPRX Discussion

投稿を表示

最近閲覧した銘柄